<p>Table S1. Treatment recommended by the ARIA guidelines 4 for the 4 fictitious case scenarios (* decongestant: a short course (<10 days) of oral or nasal decongestant); ALT: antileukotriene Case 1: Patient, currently untreated, is allergic to house dust mite and suffering from rhinorrhea, sneezing and nasal congestion since 2 months. Symptoms impair the quality of sleep. ARIA classification group Moderate-severe persistent allergic rhinitis</p><p>Treatment recommended by ARIA guidelines Nasal corticosteroid +/- H1-antihistamine or ALT+/- decongestant(*) +/- allergen avoidance</p><p>Case 2: Patient, currently untreated, with symptoms of sneezing, runny nose, red and tearing eyes since 1 month, especially when working in the garden. Besides these symptoms, the patient has no complaints. ARIA classification group Mild intermittent allergic rhinoconjunctivitis Treatment recommended by ARIA guidelines Oral H1-antihistamine +/- decongestant(*) +/- allergen avoidance Or Nasal H1-antihistamine or ALT + ocular chromone or H1-antihistamine +/- decongestant(*) +/- allergen avoidance Case 3: Patient, currently untreated, allergic to birch, is especially suffering from nasal congestion for the last 2 weeks. The patient is in the middle of exams and his symptoms interfere with studying. ARIA classification group Moderate-severe intermittent allergic rhinitis Treatment recommended by ARIA guidelines Oral or nasal H1-antihistamine or ALT +/- decongestant(*) +/- allergen avoidance Or Decongestant(*) +/- allergen avoidance Or Nasal corticosteroid +/- decongestant(*) +/- allergen avoidance</p><p>Case 4: Patient with severe symptoms of allergic rhinitis due to house dust mite for many years. Current treatment with oral antihistamine provides insufficient symptom relief. ARIA classification group Moderate-severe persistent allergic rhinitis, step-up treatment oral antihistamine Treatment recommended by ARIA guidelines Nasal corticosteroid +/- decongestant(*) +/- allergen avoidance Or Nasal corticosteroid + oral or nasal H1-antihistamine or ALT +/- decongestant(*) +/- allergen avoidance Table S2. Treatment modalities selected in 4 case scenarios of allergic rhinitis. </p><p>Treatments consistent with the ARIA guidelines [4] are in bold </p><p>Clinical scenario 1 % (n) </p><p>Selected treatment or combination of treatments </p><p>AA + OAH/NAH + NGCS 38.3 % (134) </p><p>OAH/NAH + NGCS 16.3% (57) </p><p>AA + OAH/NAH + ODC/NDC + NGCS 9.7% (34) </p><p>AA + NGCS 9.1% (32) </p><p>OAH/NAH + ODC/NDC + NGCS 5.7% (20) </p><p>NGCS 4.6% (16) </p><p>AA + OAH/NAH 3.1% (11) </p><p>AA + OAH/NAH + ODC/NDC 3.1% (11) </p><p>OGCS 1.7% (6) </p><p>OAH/NAH + ODC/NDC 1.4% (5) </p><p>OAH/NAH 1.4% (5) </p><p>AA + ODC/NDC + NGCS 0.8% (3) </p><p>IT 0.6% (2) </p><p>AA + NGCS + LTRA 0.3% (1) </p><p>OAH + NGCS +LTRA +/- AA 0.6% (2) </p><p>Other 3.1% (11) </p><p>Consistent with ARIA recommendations 84.8% (297) </p>